BLB Solicitors - The Leading Chronic Pain & CRPS Solicitors
BLB Solicitors - The Leading Chronic Pain & CRPS Solicitors
  • Home
  • About Us
    • Andrew Atkinson
    • Bruce Dyer
    • Clare Lowes
    • David Gazzard
    • Mark Tawn
    • Richard Lowes
  • Pain Conditions
    • CRPS Compensation
    • Fibromyalgia Solicitors
    • Myofascial Pain Syndrome Compensation Claim
    • Somatic Symptom Disorder Compensation Claim
    • Neuropathic Pain Compensation Claim
    • Functional Neurological Disorder Compensation
    • Chronic Fatigue Syndrome (ME) Compensation Claim
    • Chronic Pain Syndrome Compensation Claim
  • Unhappy With Your Solicitor?
  • Case Studies
    • Testimonials
  • Blog
  • Contact Us

Home » Could spider venom hold the key to treating chronic pain?

Rehabilitation and Treatment Feb 11th, 2022
King Baboon Spider

Could spider venom hold the key to treating chronic pain?

Visit our comprehensive Chronic Pain information hub.

It may be counterintuitive to associate animal venom of any kind with developments in the treatment of chronic pain. However, five years ago, we reported on the discovery of the pain-relieving benefits of a compound known as Rg1A, which is found in the venom of a type of predatory sea snail. Laboratory tests on rats confirmed that injecting the compound not only relieved pain, but that its effects were relatively long-lasting compared to other drug therapies. Another benefit is that Rg1A is non-addictive. In light of these discoveries, it seems surprising that little has been heard of Rg1A since.

Now, researchers in Australia have published a paper on another compound, Pm1a, found in the venom of the rather terrifyingly-named King Baboon Spider. While not fatal, its bite is extremely painful, and the effects can last for several days. Breaking down the venom into its various components, the team believes that one of them – Pm1a – is responsible for its potency. It appears that Pm1a plays a significant role in our brain feeling pain through the central nervous system. The mechanism by which it achieves this is technical but put simply, Pm1a acts on multiple ion channels in the body, causing pain neurons to continue firing repeatedly.

The team says that understanding this mechanism could lead to new drug therapies that inhibit the excitability of the neurons in these channels, reducing or even eliminating pain.

Andrew Atkinson
Make an Enquiry

Contact Us

Contact Form

Left Column

Right Column

Centre

 
Sending

Recent Articles

  • Meet your chronic pain solicitor: Andrew Atkinson
  • CRPS on the rise but 62% of the UK have never heard of it
  • New fibromyalgia diagnostic guidelines
  • Could spider venom hold the key to treating chronic pain?
  • Study suggests Botox can prolong the benefit of a nerve block for CRPS

Share this Article

Newsletter Sign-up

* indicates required

Legal Glossary

Find Out More

You may also like...

  • Jan 6th, 2022
    Study suggests Botox can prolong the benefit of a nerve block for CRPS
    Read Article
View All Related Articles

Get in Touch Today

Contact Form

Left Column

Right Column

Centre

 
Sending

1 Edgar Buildings,
George Street,
Bath, BA1 2DU

01225 462871 01225 445060
Authorised & Regulated by Solicitors Regulation Authority (No. 636644).
©2022 BLB Solicitors  |  Privacy & Terms